Table 2.
Ameliorative effect of gallic acid pre-treatment and co-treatment on methotrexate-induced changes in plasma biomarkers of renal and hepatic function in rat.
| Group Parameter | Control | MTX | MTX + GA (pre-treated) | MTX + GA (co-treated) | GA |
|---|---|---|---|---|---|
| Creatinine (mg/dL) | 0.98±0.13 | 2.2±0.1* | 1.4±0.1a | 1.5±0.1a | 1.2±0.1 |
| Urea (mg/dL) | 35.0±1.2 | 59.0±2.6* | 43.2±2.3a | 45.5±3.2a | 39.4±2.9 |
| TBILI (mg/dL) | 0.36±0.02 | 0.86±0.03* | 0.47±0.02a | 0.49±0.02a | 0.43±0.02 |
| ALP (U/L) | 157.4±6.4 | 406.8±7.3* | 268.8±1.9a | 327.4±1.4a | 287.0±7.5 |
| ALT (U/L) | 21.5±1.6 | 43.6±2.4* | 26.9±1.6a | 33.0±2.2a | 26.8±2.4 |
| AST (U/L) | 147.2±5.3 | 284.1±6.3* | 195.3±4.8a | 240±5.7a | 193.4±3.8 |
| GGT (U/L) | 1.5±0.2 | 3.9±0.2* | 2.1±0.1a | 2.3±0.1a | 1.7±0.2 |
Data are expressed as mean ± S.D for six rats in each group.
*Significantly different from the control (P<0.05);
asignificantly different from the methotrexate group (P<0.05); values in parenthesis represent percentage (%) increase.